Download in electronic PDF format for $75

Abstract:  Even when a diagnosis of prostate cancer is anticipated, many patients are unprepared for the persistence and severity of sequelae such as erectile dysfunction, which frequently results from lifesaving treatment for that disease. Erectile dysfunction in particular can exert a powerful impact on quality of life as the patient’s self-esteem diminishes, intimacy erodes, and a sustained level of stress and anxiety that impairs work performance and personal relationships becomes a part of his everyday experience. The Stanley Prostate-cancer Protocol for treating erectile dysfunction after prostatectomy and/or radiotherapy was developed to better assist the underserved patient population faced with that challenge. Feedback from patients and prescribers indicates that this program, even when initiated years after treatment for prostate cancer, is consistently effective in treating erectile dysfunction. The authors have also found that incorporating the Protocol into a range of pharmacy services can further the growth of a compounding practice. In this case report, the outcome of Stanley-Protocol therapy in a patient complaining of complete and persistent erectile dysfunction after prostate-cancer treatment is presented and formulations used in therapy for that disorder are provided.

Related Keywords: prostate cancer, prostatectomy, post-therapy erectile dysfunction, surgical complication, Stanley protocol, adverse effect, case report, formulations, urologic surgery, depression, self esteem, quality of life, sexual function, tadalafil, nitric oxide, penile blood flow, sildenafil, vacuum erection device, Kegel exercises, oral troche, drug bioavailability, intracavernosal penile injection, prostaglandin E1, phentolamine mesylate, papaverine hydrochloride, trimix, personalized care

Related Categories: CANCER AND AIDS, FORMULATIONS, MENTAL HEALTH, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CASE REPORTS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, UROLOGY/URINARY TRACT

Printer-Friendly Version

Download in electronic PDF format for $75

Abstract:  Even when a diagnosis of prostate cancer is anticipated, many patients are unprepared for the persistence and severity of sequelae such as erectile dysfunction, which frequently results from lifesaving treatment for that disease. Erectile dysfunction in particular can exert a powerful impact on quality of life as the patient’s self-esteem diminishes, intimacy erodes, and a sustained level of stress and anxiety that impairs work performance and personal relationships becomes a part of his everyday experience. The Stanley Prostate-cancer Protocol for treating erectile dysfunction after prostatectomy and/or radiotherapy was developed to better assist the underserved patient population faced with that challenge. Feedback from patients and prescribers indicates that this program, even when initiated years after treatment for prostate cancer, is consistently effective in treating erectile dysfunction. The authors have also found that incorporating the Protocol into a range of pharmacy services can further the growth of a compounding practice. In this case report, the outcome of Stanley-Protocol therapy in a patient complaining of complete and persistent erectile dysfunction after prostate-cancer treatment is presented and formulations used in therapy for that disorder are provided.

Related Keywords: prostate cancer, prostatectomy, post-therapy erectile dysfunction, surgical complication, Stanley protocol, adverse effect, case report, formulations, urologic surgery, depression, self esteem, quality of life, sexual function, tadalafil, nitric oxide, penile blood flow, sildenafil, vacuum erection device, Kegel exercises, oral troche, drug bioavailability, intracavernosal penile injection, prostaglandin E1, phentolamine mesylate, papaverine hydrochloride, trimix, personalized care

Related Categories: CANCER AND AIDS, FORMULATIONS, MENTAL HEALTH, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CASE REPORTS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, UROLOGY/URINARY TRACT

Printer-Friendly Version